Alzheimer's disease (AD) is leading cause of death among older characterized by neurofibrillary tangles, oxidative stress, progressive neuronal deficits, and increased levels 
donepezil, rivastigmine, and galantamine are entirely accepted, and therefore, the latter three are extensively used for the symptomatic therapy of mild-to-moderate AD. 6 The cortical cholinergic dysfunction begins 7 in midlife and is closely followed by increases in deposition of cortical Aβ levels.
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In addition to the cholinergic neurotransmission, glutamate is the main excitatory neurotransmitter, which plays an important role in 
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Glutamate receptors specially NMDA-mediated excitotoxicity are major factors responsible for Aβ-induced neuronal death; therefore, NMDA receptor antagonist is used for progression of AD, and thus, memantine is one such agent that has been accepted in European
Union and Australia, although US-FDA has approved it very recently in October 2003.
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The major limitation of both cholinergic agonists and glutamate receptor antagonists is that they produce the withdrawal effect and only delay the progression of neuronal degeneration but unable to cure this chronic disorder. Therefore, there is a need to explore novel target site for drug discovery in this area.
| PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE
Alzheimer's disease (AD) is considered by neurofibrillary tangles, oxidative stress, progressive cholinergic neuron degeneration, and subsequently leads to decreased levels of choline acetyltransferase 
Key Points
• CGRP enhances the expression of AChR (acetylcholine receptors).
• CGRP inhibits the release of acetylcholinesterase (AChE).
• Donepezil releases the CGRP and produces the angiogenesis and neurogenesis by releasing of insulin-like growth factor 1(IGF-1).
• CGRP (-/-) knockout mice do not produce memory enhancement and any neurogenesis and angiogenesis.
• CGRP enhances CREB phosphorylation and attenuates Tau protein phosphorylation in rat brain during focal cerebral ischemia and increases blood flow.
| BIOLOGY OF CALCITONIN GENE-RELATED PEPTIDE (CGRP)
Calcitonin gene-related peptide (CGRP) is a thirty-seven-amino acid regulatory neuropeptide resulting from different merging of the CGRP gene. There are two forms which are generated by mRNA processing:
one is αCGRP which is predominant in central peripheral system as well as in several endocrine tissues, and the other is βCGRP which differs in single amino acid sequence from αCGRP and is located in brain, sensory ganglia, and thyroid gland. The αCGRP efficiently plays a role in response to painful provocations, cardiovascular homeostasis, digestive behavior, and mineral metabolism, while βCGRP roles as neuroactive regulators and hormones and the importance of these peptides in normal brain development. 11, [33] [34] [35] [36] Other members like adrenomedullin, amylin, calcitonin, intermedin, and calcitonin receptor-stimulating peptide have same homology with the CGRP. 
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Binding of CGRP to its receptor accumulation of the cAMP level by coupling with Gs protein 44, 45 will further activate the PKA and PI3 kinase and PKC, which enhance the effect of Ach receptor. 46, 47 CGRP1-4, CGRP1-5, and CGRP1-6 fragments reversibly and quickly, without directly activating those receptors, improve the agonist sensitivity of nAChRs 48 and, along with this, boost the noncontractile Ca CGRP receptors raise cAMP levels and downregulate the availability of acetylcholinesterase at transcription level. 50 Previously, it has been shown that CGRP raises mRNA levels of α-subunit of acetylcholine receptor (AChR) in the brain, via the mediation of PKA, 50, 51 and produces the sympathetic innervation. Additionally, the concentration of Ang-IV and Ang (3-7) raises due to activation of brain RAAS by the AChR. 52, 53 It acts via the presence of AT4 receptor in cerebellum, amygdala, neocortex, hippocampus, basal ganglia, other cholinergic nuclei, and some peripheral tissue. This action enables the uptake of glucose molecule in the hippocampal neurons which produces a significant action in the Alzheimer's type dementia for angiogenesis. 54, 55 F I G U R E 1 Alternative pathway of calcitonin gene-related peptide (CGRP) for treatments of Alzheimer's type dementia AT4 receptor is useful for internalization of calcium in the cell that further activates intracellular to extracellular metalloproteinases for neural plasticity action (LTP). 56, 57 It has been recommended that exogenous administration of CGRP inhibits infiltration of macrophages and expression of various inflammatory mediators such as NFkB, IL-1b, TNF-α, iNOS, MMP-9, and cell adhesion molecules like ICAM-1 which attenuates consequence of inflammation in AD. 58, 59 However, shortterm treatment of ACE inhibitors does not restore CGRP-mediated cognitive as well as vascular functions, but long-term administration improves cognitive functions.
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In addition, chronic administration of donepezil, a cholinesterase inhibitor, has been reported to inhibit acetylcholinesterase and produce angiogenesis and neurogenesis in the dentate gyrus of the hippocampus and improve spatial learning due to the releasing CGRP and subsequently increase sensory insulin-like growth factor 1 (IGF-I) in the mouse brain. There was no any observable effect after administration of donepezil in CGRP-knockout mice, further exposing mice to functional denervation of sensory neurons. 61 Furthermore, during focal cerebral ischemia, CGRP improves CREB phosphorylation, decreases
Tau protein phosphorylation in mice brain, increases blood flow, and involves in the protective effect to ischemic neurons 62 ( Figure 1 ).
| CONCLUSION
It may be suggested on the basis of existing evidence that CGRP prevents the continuation of AD by inhibiting of acetylcholinesterase 
